SANOFI-AVENTIS (EPA:SAN) Press Release: Completed XTEND-Kids Phase 3 study strengthens potential of ALTUVIIIOTM to redefine expectations for treatment of children <12 years of age with hemophilia A
Directive transparence : information réglementée
02/03/2023 08:00
27/10/2023 07:31
27/10/2023 07:31
22/10/2023 21:00
22/10/2023 21:00
18/10/2023 10:45
18/10/2023 10:45
17/10/2023 20:18
17/10/2023 20:18
13/10/2023 16:00
13/10/2023 16:00